“钠-葡萄糖共转运蛋白-2（SGLT-2）抑制剂的心肾保护作用已被多项大规模、多中心临床试验证实。2023年4月，亚太肾脏病学会颁布了《亚太地区SGLT-2抑制剂的专家共识》（以下简称本共识），结合亚太地区的文化与风俗，聚焦于SGLT-2抑制剂的应用 ...

Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors ...

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

“2型糖尿病，这一全球性流行病，正悄然影响着近5亿成年人的健康，带来沉重的疾病负担。近年来，科学家们不断探索2型糖尿病与肿瘤之间的复杂关系——高胰岛素血症、高血糖状态和慢性炎症等多种机制，可能成为肿瘤发生和发展的“推手”。那么，作为新型降糖药物的钠- ...

Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

随着患者使用 SGLT2 抑制剂时间的延长，进展为重度主动脉瓣狭窄的风险逐渐降低：使用至少 3 个月 、 6 个月、 12个月 的，进展为重度主动脉瓣狭窄风险分别降低 46%、 52%和 72%。 研究者分析 ，其作用机制可能是多种途径共同作用的结果，有研究发现， 钙化的主动脉瓣叶上 SGLT2 受体过度表达，可以推断，通过抑制这些受体来减轻炎症和细胞内钙含量，能够降低病情进展速度。 研究者还指出 ...